biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Feb 21, 2023 12:00pm

377 Views

Post# 35296445

Is this the week?

Cash is low, low, low...
March is closing in fast.

Midatech was able to raise money with Ladenberg Thalmann and BTI was valued at 2.3X more valuable than Midatech in the BTI/Midatech transaction by my calculation which was validated by Armistice Capital. Midatech praised the existing xB3 partnerships and potential US$200 million milestone payments PLUS royaties after its due diligence on xB3. J&J has since extended, expanded, and payed a small milestone for its multi-product xB3 agreement it appears.

At $.025 BTI should be able to do a complete recapitalization at worst given the above.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities